Skip to main content
RT @AurelieRheumo: 🔜 Remission in PsA : the earlier the better ⏰
Dutch cohort (DEPAR) 300+pts
Failure to achieve MD

Aurelie Najm AurelieRheumo

4 years 3 months ago
🔜 Remission in PsA : the earlier the better ⏰ Dutch cohort (DEPAR) 300+pts Failure to achieve MDA 1yr post diagnosis 🧨worst QoL yr 1️⃣2️⃣&3️⃣ 🧨↗️bioDMARDs use over time 🧨no recovery #OP0028 #EULAR2022 @RheumNow https://t.co/IS6ySIQvBP
RT @drdavidliew: PMR bursas are filled with macrophage subtypes esp CD68+, expressing IL-6 & GM-CSF.

PMR is now far

David Liew drdavidliew

4 years 3 months ago
PMR bursas are filled with macrophage subtypes esp CD68+, expressing IL-6 & GM-CSF. PMR is now far from just a vibe - real science, real targets for therapy. Not every day that PMR basic science makes it on stage, lovely from @VasculitisUMCG @jiemy_william #EULAR2022 @RheumNow https://t.co/zem3JEosQL
RT @RichardPAConway: Jiemy et al. Phenotyping monocytes/macrophages in PMR. Synovial/bursal macrophages have pro-inflamm

Richard Conway RichardPAConway

4 years 3 months ago
Jiemy et al. Phenotyping monocytes/macrophages in PMR. Synovial/bursal macrophages have pro-inflammatory phenotype with prominent IL-6 and GM-CSF response. Rationale for tocilizumab/mavrilimumab @RheumNow #EULAR2022 OP0015 https://t.co/53GJkL4BcP
RT @AurelieRheumo: Retrospective nation-wide italian study:
Long term exposure to :
🌫 PM10 ⬆️ risk of RA aOR 1.4

Aurelie Najm AurelieRheumo

4 years 3 months ago
Retrospective nation-wide italian study: Long term exposure to : 🌫 PM10 ⬆️ risk of RA aOR 1.4 but not other AI diseases 🚗PM2.5 ⬆️ risk of RA aOR 1.6 CTDs aOR 1.1 IBDs aOR 1.2 OP0071 #EULAR2022 @Rheumnow https://t.co/HOOEnh7KWW
RT @KDAO2011: Pre-clinical RA TREAT EARLIER Trial: #Plenary OP0070
RDBPCT eval temporary MTX vs PCB in 136 pts with art

TheDaoIndex KDAO2011

4 years 3 months ago
Pre-clinical RA TREAT EARLIER Trial: #Plenary OP0070 RDBPCT eval temporary MTX vs PCB in 136 pts with arthralgias >2 weeks at risk for RA (MRI hand/forefoot w/subclinical inflammation) followed for 2 yrs; 1/3 +ACPA. Rx 1 yr can delay but won’t prevent RA. #EULAR2022 @rheumnow https://t.co/v1GWOBFstz
EULAR 2022 Featured Industry Abstracts

Review is a collection of several EULAR 2022 abstracts highlighted in recent pr

Dr. John Cush RheumNow

4 years 3 months ago
EULAR 2022 Featured Industry Abstracts Review is a collection of several EULAR 2022 abstracts highlighted in recent press releases from companies sponsoring major clinical trials. You can search the EULAR site for these abstract and others here. https://t.co/ggnAyuvAbl https://t.co/WjKDb70RkW
RT @Yuz6Yusof: #OP0002 #EULAR2022 What immune tests to monitor during pregnancy in #lupus? A meta-analysis found:

💠3

Md Yuzaiful Md Yusof Yuz6Yusof

4 years 3 months ago
#OP0002 #EULAR2022 What immune tests to monitor during pregnancy in #lupus? A meta-analysis found: 💠32% had a flare (new IS or Pred>9mg/d) 💠⬇️C3 and/or C4 in 1st Trimester predicted LN or SLE flare Worth checking C3/C4 in each trimester @RheumNow https://t.co/fPEXwReK7u https://t.co/BX6fzKzfvC
RT @Yuz6Yusof: #POS0183 #EULAR2022 Pooled analyses of 5 Belimumab RCTs showed better response vs PBO in those:

💠SLED

Md Yuzaiful Md Yusof Yuz6Yusof

4 years 3 months ago
#POS0183 #EULAR2022 Pooled analyses of 5 Belimumab RCTs showed better response vs PBO in those: 💠SLEDAI=>10 💠dsDNA+ve + ⬇️C3 and/ ⬇️C4 💠⬇️C3 and/ C4 pre-treatment 💠Response high regardless SDI, Steroid, #lupus duration @RheumNow https://t.co/fLggazbRQu
RT @AshimaMakol: ✨Localized #Scleroderma Pearls✨
#EULAR2022

Eosinophilic Fasciitis
👉Contractures wrists/ankles,

Ashima Makol MD AshimaMakol

4 years 3 months ago
✨Localized #Scleroderma Pearls✨ #EULAR2022 Eosinophilic Fasciitis 👉Contractures wrists/ankles, rarely fingers 👉Mimics- #Lipodermatosclerosis #Panniculitis 👉GCs+MTX 1st line (IV in refractory🧐),MMF 2nd line ✅I add IVIg+/-UVA1 (pending logistics and insurance coverage!) https://t.co/ZErfLxgdxd
RT @RichardPAConway: Hellamand et al. Sex differences in first TNFi response in AxSpA. Treatment efficacy (RR 0.85) and

Richard Conway RichardPAConway

4 years 3 months ago
Hellamand et al. Sex differences in first TNFi response in AxSpA. Treatment efficacy (RR 0.85) and retention (58% vs 72% month 24) rates lower in females. @RheumNow #EULAR2022 OP0020 https://t.co/2IL88K7q40 https://t.co/hSJds5EJFK
RT @RichardPAConway: TOFFIFE RCT in colchicine-resistant FMF. Tocilizumab normalises SAA and CRP/ESR with PGA response i

Richard Conway RichardPAConway

4 years 3 months ago
TOFFIFE RCT in colchicine-resistant FMF. Tocilizumab normalises SAA and CRP/ESR with PGA response in 20-25%. Maybe response criteria too strict, or maybe TCZ only effective for subgroup of patients @RheumNow #EULAR2022 OP0043 https://t.co/kNs8DMzXFB https://t.co/QMDk1IUkjx
RT @RichardPAConway: Adami et al on risk of RMDs with air pollution. Mainly RA - OR 1.4 for PM10, 1.6 for PM2.5 @RheumNo

Richard Conway RichardPAConway

4 years 3 months ago
Adami et al on risk of RMDs with air pollution. Mainly RA - OR 1.4 for PM10, 1.6 for PM2.5 @RheumNow #EULAR2022 OP0071 https://t.co/zDr2jMsIWv https://t.co/f0Y2rQxWRD
RT @Janetbirdope: Can you train #dermatologists to do ultrasound to detect #PsA if pt has joint pain. POCUS of up to 3 p

Janet Pope Janetbirdope

4 years 3 months ago
Can you train #dermatologists to do ultrasound to detect #PsA if pt has joint pain. POCUS of up to 3 painful joints. US ⬆️derm suspicion of PsA- but this is not feasible in busy offices and no reimbursement @RheumNow #EULAR2022 @eular_org OP0029 https://t.co/9a3gDgIBp0
RT @ericdeinmd: #EULAR2022 TREAT-EARLIER OP0700
Arthralgia + subclinical inflammation in MRI without RA, treated with MT

Eric Dein ericdeinmd

4 years 3 months ago
#EULAR2022 TREAT-EARLIER OP0700 Arthralgia + subclinical inflammation in MRI without RA, treated with MTX + depo steroid injection ▶️In High risk patients, delayed development of synovitis, but does not prevent in long-term ▶️Reduction in disease burden on MTX Rx @RheumNow https://t.co/SKlqMQQTui
RT @RichardPAConway: Zhao et al. Infection risk is ⬆️ in incident AAV. aHR 3.8 for first infection and 3.8 for infec

Richard Conway RichardPAConway

4 years 3 months ago
Zhao et al. Infection risk is ⬆️ in incident AAV. aHR 3.8 for first infection and 3.8 for infectious mortality. 3.2 fold increase in number infections. @RheumNow #EULAR2022 OP0093 https://t.co/LSe4vJqZym https://t.co/tNqI2m30SD
×